March 2012 | Oncology & Biotech News

April 17, 2012

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

April 17, 2012

The USC Norris Comprehensive Cancer Center and Hospital has long enjoyed a national reputation as a leading resource for cancer research, treatment, prevention, and education.

April 16, 2012

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.

April 13, 2012

Adding oxaliplatin to conventional chemotherapy increases survival in patients with advanced colon cancer in a broad range of community practice settings.

April 13, 2012

Shrinking reimbursements and higher healthcare costs are making it difficult for community oncologists to stay in practice.

April 12, 2012

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

April 11, 2012

Being newly diagnosed with lung or colorectal cancer is often not sufficient to motivate cigarette smokers to quit.

April 10, 2012

Thanks to earlier detection and improved treatment, the population of cancer survivors has increased dramatically and will continue to increase as the baby boomers age.

April 10, 2012

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

April 05, 2012

The concept of dose titration in patients with mRCC who fail to achieve therapeutic levels on axitinib was validated by a secondary analysis.

April 05, 2012

The addition of everolimus to standard octreotide LAR achieved about a 5-month improvement in progression-free survival in patients with advanced neuroendocrine tumors.

April 04, 2012

A new test specifically designed for breast cancer patients with DCIS appears to be a better indicator of recurrence than other assays for more invasive forms of the disease.

April 04, 2012

Patients who undergo chemotherapy for breast cancer may develop fatigue that remains problematic long after they complete treatment.

April 03, 2012

An interview with Nicholas J. Vogelzang, MD, during the ASCO 2012 Genitourinary Cancers Symposium, about treatment of prostate cancer and unmet needs.

April 03, 2012

Adjuvant chemotherapy improves disease-free and overall survival in many--but not all--patients with breast cancer.

April 02, 2012

EBRT led to more long-term toxicity and higher treatment-related costs compared with radical prostatectomy or brachyherapy.

April 02, 2012

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

April 02, 2012

An immunoassay to detect the presence of PAM4 showed promise for the detection and diagnosis of early-stage pancreatic ductal adenocarcinoma.

March 30, 2012

The investigational agent MDV3100 extended survival in men with late-stage castration-resistant prostate cancer in the phase III AFFIRM trial.

March 30, 2012

More research is needed to define molecular subtypes of gastric cancer and identify appropriate targets for clinical use.

March 29, 2012

For locally advanced breast cancer, molecular profiling may be an effective way to determine which patients respond better to certain therapies.

March 28, 2012

For patients with metastatic colorectal cancer that has progressed on multiple lines of standard therapy, regorafenib may be a new treatment option that achieves disease control.

March 28, 2012

Preoperative gemcitabine plus cisplatin followed by radical surgery is feasible, tolerable, and active in patients with early-stage non-small cell lung cancer.

March 27, 2012

Patients who are obese before being diagnosed with colorectal cancer are more likely to die of their disease than patients who are at a normal weight prediagnosis.

March 26, 2012

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

March 26, 2012

Complementary! Sounds good, how could it hurt? When applied in cancer therapy, however, what sounds good may not always be good for patients.